Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The research conducted by Professor Zou Zui and his team focuses on the immunoregulatory mechanisms in sepsis. As a ...

BackgroundSepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction. It ...

An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. On November 4, 2025, Pasithea Therapeutics Corp announced the ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

A new report from OKRs Tool reveals what actually drives OKR success inside fast-moving startups. Based on responses from over 200 early- and growth-stage companies, the 2026 OKR Benchmark Report ...

New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial ...

Verastem ( ($VSTM) ) has issued an update. On November 4, 2025, Verastem Oncology reported its third-quarter financial results and business ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

Shutterstock, Inc. (the "Company"), a family of brands delivering scalable creative and GenAI solutions to help customers fuel great work, today announced financial results for the third quarter ended ...

The company expects to share safety and efficacy results from the RAMP-205 expansion cohort in first-line advanced pancreatic cancer and initial results from the Phase I/IIa trial evaluating VS-7375 ...